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Abstract: We investigated nozzleless ultrasound-enhanced electrospinning (USES) as means to
generate nanofibrous drug delivery systems (DDSs) for pharmaceutical and biomedical applications.
Traditional electrospinning (TES) equipped with a conventional spinneret was used as a reference
method. High-molecular polyethylene oxide (PEO) and chitosan were used as carrier polymers and
theophylline anhydrate as a water-soluble model drug. The nanofibers were electrospun with the
diluted mixture (7:3) of aqueous acetic acid (90% v/v) and formic acid solution (90% v/v) (with a
total solid content of 3% w/v). The fiber diameter and morphology of the nanofibrous DDSs were
modulated by varying ultrasonic parameters in the USES process (i.e., frequency, pulse repetition
frequency and cycles per pulse). We found that the USES technology produced nanofibers with
higher fiber diameter (402 ± 127 nm) than TES (77 ± 21 nm). An increase of a burst count in USES
increased the fiber diameter (555 ± 265 nm) and the variation in fiber size. The slight-to-moderate
changes in a solid state (crystallinity) were detected when compared the nanofibers generated by TES
and USES. In conclusion, USES provides a promising alternative for aqueous-based fabrication of
nanofibrous DDSs for pharmaceutical and biomedical applications.
Keywords: nanotechnology; nanofibers; traditional electrospinning; ultrasound-enhanced electrospinning;
drug delivery system
1. Introduction
Electrospinning (ES) is a method for fabricating polymeric nanofibrous constructs, which
have potential applications in pharmaceutical and biomedical fields. Nanofibers are typically
tenth-to-hundred nanometers thick, they feature large outer surface, substantial surface- area-to-volume
ratio, and high porosity (nanomats). This makes these fibers interesting for drug delivery and tissue
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engineering applications [1–3]. To date, nanofibers have found use, e.g., in formulation of poorly
water-soluble drugs, fabrication of novel drug delivery systems (DDSs), supporting wound healing as
wound dressings or artificial skin substitutes, and as scaffolds in tissue engineering [3–5].
ES has been applied as a manufacturing method in the clothing, electronics and optical industries,
and during the past twenty years it has gained increasing interest in the pharmaceutical and biomedical
industries. In traditional ES (TES), a polymer solution is first translated via a capillary tube to a
spinneret and then spun towards a grounded collector plate or roll using a high-voltage electron field
between the spinneret and collector [6,7]. The major limitations associated with the use of a simple
single-fluid TES are blockage of a spinneret (nozzle) system, hazards related to the use of organic
solvents (including residual solvent in the nanofibers), and long processing times. More recently,
modified two-fluid and tri-fluid coaxial ES methods have been introduced to advance ES of even
complicated nanostructures [8]. The clogging phenomena associated with ES can be eliminated by
using such modified coaxial ES and concentric needle spinneret [8]. The morphology and diameter of
TES nanofibers depend on the intrinsic properties of the solution, the type of polymer, conformation of
the polymer chain, the viscosity, elasticity, electric conductivity, as well as the polarity and surface
tension of the solvent [1–4]. In recent years, interest has been focused on developing nozzleless ES
technologies to avoid the above-mentioned challenges related to TES.
Ultrasound-enhanced ES (USES) provides an orifice-free ES technique that employs ultrasound
(US) to create nanofibers [9]. In this technique, high-intensity focused US bursts generate a liquid
protrusion with a Taylor cone from the surface of an electrospinning solution (Figure 1). When the
drug-polymer solution is charged with high negative voltage, a nanofiber jet is generated from the tip
of the protrusion and this jet is led to an electrically grounded collector residing at a constant distance
from the fountain [10]. The USES have some advantages over TES: the blockage of a spinneret system
and the inclusion of hazardous organic solvents can be avoided with USES. In a USES setup, there is no
nozzle that may clog and the evaporation of solvent is more efficient than in a TES setup. With USES,
the evaporation of solvent is advanced by using a high-intensity focused US. A travelling US wave
generates acoustic streaming inside the solution and induces thermal effect (heating) on the surface of the
liquid, thus advancing the evaporation of the solvent. The generation of a liquid protrusion with a Taylor
cone can be modified by changing US frequency, pulse repetition frequency and cycles per pulse [9,10].
Figure 1. (A) Schematic diagram of the ultrasound-enhanced electrospinning (USES) setup, (B) photograph
of the USES system and process environment (including a humidity cabinet), and (C) close-up
photograph on the formation of nanofibers in a USES process.
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In the present study, we compared the TES and USES techniques as means to fabricate drug-loaded
polymeric nanofibers and we investigated the physicochemical and pharmaceutical properties of the
produced nanofibers/nanofibrous DDSs. The influence of these two nanofabrication processes on the
fiber formation, geometric fiber properties, surface morphology and physical solid-state properties
of nanoconstructs were investigated. Special attention was paid to the formation and physical
characterization of the drug-loaded nanofibers generated by the USES method.
2. Materials and Methods
2.1. Materials
Theophylline anhydrate (CAS No. 58-55-9; chemical purity ≥ 99%; Sigma-Aldrich Inc., Saint Louis,
MO, U.S.A) was used as a water-soluble model drug. Polyethylene oxide, PEO (CAS No. 25322-68-3;
Product No. 189456; average molecular weight 900,000 Da) and chitosan (CAS No. 9012-76-4; Product
No. 448877; medium molecular weight grade) (Sigma-Aldrich Inc., Saint Louis, MO, U.S.A) were
investigated as carrier polymers in both TES and USES nanofabrication. The diluted mixture (7:3) of
aqueous acetic acid (CAS No. 64-19-7; chemical purity 99.9%) (90% v/v) and formic acid (CAS No.
64-18-6; chemical purity ≥ 98%; Ph. Eur., Strasbourg, France) solution (90% v/v) (with a total solid
content of 3% w/v) was used as a solvent system for ES.
2.2. Fabrication of Nanoconstructs
The composition of the electrospun nanofibers is shown in Table 1. The nanofibers were generated
in a TES (ESR-200Rseries, eS-robot®, NanoNC, Seoul, Korea) and in a custom-made in-house USES
method. The USES method is described in detail in [8]. In brief, the USES setup features a vessel
containing a spinning solution, a US generator and a transducer, a membrane system between the
bottom of the vessel and the US transducer, a high-voltage electrode, and a grounded collector plate.
Table 1. Composition (% w/w) of nanofibers generated by traditional electrospinning (TES) (I) and
ultrasound-enhanced electrospinning (USES) (II–IV.)
Formulation/Ingredient I II III IV
Chitosan 43.5 43.5 34.8 40
Polyethylene oxide (PEO) 43.5 43.5 52.2 60
Theophylline 13.0 13.0 13.0 0
To modulate the fiber diameter, specific US parameters (frequency, pulse repetition frequency
and cycles per pulse) were exploited in an ES process. Table 2 lists the process parameters applied to
fabricate TES and USES nanofibers.
Table 2. Process parameters applied in the traditional electrospinning (TES) (I) and ultrasound-enhanced
electrospinning (USES) (II–IV) of nanofibers.
Formulation/Parameter I II III IV
Voltage (kV) 11.5–14.0 16.0 16.0 14.0–16.0
Voltage of collector (kV) NA −5.0 −5.0 −5.0
Distance (cm) 15.0 17.0 17.0 17.0
Pumping rate (mL/h) 0.3 0.8 0.6 0.6
Amplitude (mV) NA 250 240 200–240
Frequency (MHz) NA 2.06 2.06 2.06
Burst count (Cycles) NA 1000 1000 1000
Burst rate (Hz) NA 70 70 70
Humidity (RH%) 18 19 24 30
NA = not applicable.
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2.3. Characterization of Nanofibers
The nanofibrous samples were stored in a zip-lock plastic bag in ambient room temperature
(22 ± 2 ◦C) prior to characterization. Scanning electron microscopy, SEM (Zeiss EVO MA15, Jena,
Germany) and optical microscopy were applied to study fiber size distribution and morphology
of nanofibers. The samples were coated with a platinum layer (6 nm) prior to imaging with SEM.
Three SEM images of each sample were taken using three different magnifications (400×, 2000–2500×
and 10,000×). ImageJ software Version 1.51K was used to measure the diameter of nanofibers. Statistical
evaluation (t-test) was made using Microsoft Excel 2016 (Microsoft Corp., Albuquerque, NM, USA).
Physical solid-state and thermal properties were investigated by means of Fourier Transform
Infrared (FTIR) spectroscopy (IRPrestige 21, Shimadzu corporation, Kyoto, Japan) with a single
reflection attenuated total reflection (ATR) crystal (Specac Ltd., Orpington, UK), X-ray diffraction, XRD
(Bruker D8 Advance diffractometer, Bruker AXS GmbH, Karlsruhe, Germany), and differential scanning
calorimetry, DSC (DSC 4000, Perkin Elmer Ltd., Shelton, CT, USA). XRD and FTIR spectroscopy results
were normalized and scaled. In all DSC experiments, the sample size was 3–6 mg. The samples were
first cooled down and kept at 0 ◦C for three minutes, and then heated to 350 ◦C at a rate of 10 ◦C/min.
The samples were then cooled to 0 ◦C (10 ◦C/min) and then heated to 350 ◦C (10 ◦C/min). The DSC
thermogram for PEO was obtained by heating the sample from 30 ◦C to 170 ◦C with a heating rate
of 10 ◦C/min. For solid-state characterization, the corresponding binary or ternary physical mixtures
(PMs) were prepared manually with a mortar and pestle, and they were used as reference samples for
the nanofibrous samples.
3. Results and Discussion
3.1. Topographical and Fiber Size Comparison of Nanoconstructs
Figure 2 illustrates the topography (surface morphology) of the polymeric nanofibrous constructs
generated by TES (A, B) and USES (C, D). Figure 3 shows the comparison of the average diameter of
individual nanofibers produced by TES and USES. With all fiber compositions tested, TES produced
thinner and more uniform-by-size polymeric nanofibers in comparison with those generated by the
nozzle-free USES technique. The diameter of nanofibers produced by TES was 77 ± 21 nm, and the
diameter of the corresponding nanofibers generated by USES were 402 ± 127 nm (with a burst count
of 400 cycles) and 555 ± 265 nm (with a burst count of 700 cycles). Statistically significant difference
(p< 0.001) was shown between the fiber diameter of nanofibers obtained with TES and the nanofibers
generated with USES. This difference in fiber size could be explained by the fact that the USES is a
multivariate process involving an open vessel and more critical process parameters (including US
parameters) to be controlled than in the TES. The sensitivity of the polymer solution to US and the
variations in distance between the surface of the ES solution and the collector plate could be potential
reasons for these differences. In aqueous polymer solution ES, the process and ambient parameters
such as conductivity, applied voltage, relative humidity, and the distance between a nozzle tip and
collector plate could affect the diameter of nanofibers (i.e., increasing the level of these parameters
leads to generation of thinner fibers) [4]. However, in fabricating nanofibers for pharmaceutical and
biomedical applications, having nanofibers as small as possible is not of intrinsic value in itself and
is not necessarily an ultimate goal. For example, in wound healing and many tissue engineering
applications, a fiber size close to the micron-scale is considered beneficial in terms of cell adhesion and
proliferation [11].
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Figure 2. Scanning electron microscopy (SEM) images of traditional electrospun (TES) and
ultrasound-enhanced electrospun (USES) nanofibers. (A,B) TES nanofibers (magnification 2500×
and 10,000×); (C,D) USES nanofibers (2500× and 10,000×).
Figure 3. Average diameter (mean ± SD) of traditional electrospun (TES) and ultrasound-enhanced
electrospun (USES) nanofibers. The fiber size analysis is based on three SEM images, and the total
number of analyzed individual nanofibers was n = 100 (with USES 700 cycles n = 53). The number of
cycles in the USES process (US signal) refers to pulse duration.
With USES, the fiber diameter can be modulated by changing the burst count (cycles per US pulse =
duty factor). As seen in Figure 3, changing a burst count from 400 to 700 cycles generated nanofibers
with the average diameter of 402 nm and 555 nm, respectively (the other critical US parameters,
i.e., frequency and pulse repetition frequency, were kept constant). The statistical analysis showed that
the diameters of USES nanofibers generated with the two burst count cycles were different (p < 0.001).
In the TES, solutions with high conductivity and high surface tension require high voltages and the
change in applied voltage (electric field) has only a minor effect on fiber diameter of the nanofibers [4].
Therefore, the process flexibility of USES (i.e., the dynamic modulation of fiber size) is an advantage
over TES. The use of higher voltages in the TES increases also the risk of “bead” formation (= defects)
in the nanofibrous mats due to the instability of a Taylor cone [4]. As seen in Figure 2, the USES
nanofibrous constructs can be generated without signs of “beads” in the final nanofibrous mat. This is
advantageous since the formation of “beads” is considered to be a sign of improper ES process.
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3.2. Characterization of Nanoconstructs
3.2.1. X-Ray Diffraction
The carrier polymer PEO has two typical diffraction peaks (2θ) at 19◦ and 23◦ [12]. As seen in
Figure 4, both characteristic diffraction peaks of PEO are visible in the XRD patterns of the PEO powder
and in the PM, thus revealing the semi-crystalline nature of PEO. According to the literature, crystalline
theophylline gives several characteristic reflections at diffraction angles (2θ) at 7.2◦, 12.6◦, 14.3◦, 24.1◦,
25.6◦, 26.4◦ and 29.4◦ [13]. The major reflection (2θ) is located at 12.6◦. Crystalline chitosan has also
two characteristic reflections (2θ) at approximately 10◦ and 20◦ [14].
Figure 4. Normalized X-ray diffraction (XRD) patterns of pure materials, physical mixture (PM) of drug
and carrier materials, and nanofibers generated with traditional electrospinning, TES (formulation F-I),
and ultrasound-enhanced electrospinning, USES (F-II, F-III). Key: CHI = Chitosan, PEO = Polyethylene
oxide, TPH = Theophylline anhydrate form II.
The XRD patterns for the nanofibers produced by TES and USES appear nearly identical, and
the characteristic diffraction peaks for the three pure materials can be distinguished (Figure 4). Both
carrier polymers PEO and chitosan preserved their semi-crystallinity and crystallinity, respectively.
We found differences between the diffraction patterns of nanofibrous samples fabricated by these two
methods. As seen in Figure 4, nanofibers produced with TES displayed a slightly shifted diffraction
peak at 6.6◦ 2θ which suggests a solid-state change in theophylline. We also found that this reflection
and the characteristic peak of theophylline (at 7.2◦ 2θ) are absent in the XRD patterns of nanofibers
generated by USES. Moreover, the other characteristic reflection (2θ) of theophylline at 12.8◦ 2θ is
not distinguished in the XRD patterns of nanofibers (a new reflection shows less intensity and it is
shifted to 13.5◦ 2θ). Therefore, it is evident that solid-state (crystallinity) changes in theophylline have
taken place during the TES and USES nanofabrication. It is possible that in addition to an amorphous
form, theophylline monohydrate or metastable theophylline or even the mixture of different forms
may appear during or immediately after ES. Furthermore, all diffraction peaks in the XRD pattern of
the nanofibers generated by USES appear weaker and less sharp than the corresponding reflections of
the XRD pattern for the nanofibers produced by TES (Figure 4). This can be seen with the diffraction
reflection (2θ) 19.2◦ which originates from PEO. With nanofibers generated by USES, the diffraction
reflections (2θ) characteristic to semi-crystalline PEO at 19.2◦ and 23.3◦ are seen as slightly weaker
than those in the XRD pattern of PM (Figure 4). These differences in the XRD patterns reveal that there
is a difference in the crystallinity of nanofibers fabricated with the different methods. Application
of high-intensity focused US in the USES process affects the solid-state properties of the nanofibers
resulting in more amorphous (less ordered) nanostructures than those obtained with TES.
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3.2.2. Differential Scanning Calorimetry
The thermal behavior (DSC thermograms) of the pure materials, PM, and nanofibers produced
by TES and USES are shown in 5 and 6. As seen in Figure 5, the melting endotherms for PEO and
theophylline are at 70 ◦C and at 270 ◦C, respectively. The characteristic melting endotherm of PEO is
seen in the DSC thermograms of PM (Figure 5) and in the thermograms of nanofibers generated by TES
and USES (Figure 6). Chitosan as a pure material exhibited a broad endothermic event at 40–120 ◦C
(due to water evaporation) and an exothermic event at 300 ◦C (chemical degradation) [15]. The melting
of theophylline cannot be seen in the DSC thermograms of PMs and nanofibers due to the melting of
polymer at lower temperatures and subsequent dissolution of theophylline in the molten polymer
(PEO, chitosan). Hence, the DSC results cannot reveal whether theophylline exists in a crystalline form
or an amorphous form in the nanofibers generated by TES or USES. However, the XRD patterns shown
previously confirmed the solid-state of the drug (crystalline form rather than amorphous form) in the
nanofibers generated by USES.
Figure 5. Differential scanning calorimetry (DSC) thermograms of pure materials and physical mixture
(PM) of drug and carrier materials. For PEO, CHI, and PM, only the first heating is presented. Key:
CHI = Chitosan, PEO = Polyethylene oxide, TPH = Theophylline.
Figure 6. Differential scanning calorimetry (DSC) thermograms of nanofibers generated with traditional
electrospinning, TES (formulation F-I) and ultrasound-enhanced electrospinning, USES (F-II, F-III).
For F-I and F-II only the first heating is presented. Key: CHI = Chitosan, PEO = Polyethylene oxide,
TPH = Theophylline.
The DSC profiles of drug-loaded nanofibers generated by TES or USES were nearly identical
suggesting that applying focused high-intensity US in the USES process does not significantly affect
the solid-state properties of the nanofibers (Figure 6). As shown in Figure 6, the lower peak height of a
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characteristic melting endotherm for PEO at 70 ◦C indicates lower enthalpy of transition (∆H) with
the nanofibers produced by TES than that of the fibers produced by USES. In the DSC thermograms
of nanofibers generated by both TES and USES, a small exothermic event at 270 ◦C is seen, which is
probably caused by the chemical decomposition of chitosan.
In the cooling phase, only the crystallization of PEO is observed in the DSC thermogram of the
F-III nanofibers generated by USES (Figure 6). During re-heating of the sample (F-III), the thermal
event (melting endotherm) of PEO is seen. Chitosan decomposed during the first heating but the
fate of theophylline is not clear. No visible thermal events nor signals were detected in the DSC
thermogram of pure theophylline after the first heating and no decomposition during heating nor
any solidification during the cooling (Figure 5). The relatively small amount of theophylline (13%)
in the PM and nanofibers may explain why the melting of theophylline is not recognized in the DSC
thermograms of PM or nanofibers, but it cannot account for the lack of thermic events during the
cooling phase or in the second heating of pure theophylline. Crystallization of theophylline during the
DSC cooling phase has been reported previously [13,16].
3.2.3. Fourier Transform Infrared (FTIR) Spectroscopy
Figure 7 shows FTIR spectra for the pure materials, a physical mixture (PM) and the nanofibers
produced by TES and USES. No significant changes in chemical structure of the materials were found
in the nanofibers generated with TES or the USES nanofabrication process. The characteristic peaks for
theophylline were identified in both TES (F-I) and USES (F-II, III) nanofibrous constructs. The FTIR
spectra were close to identical for both types of nanofibers. A characteristic peak of PEO at 2875 cm−1
presents the stretching of C–H [17]. It can be observed in all FTIR spectra except in the spectrum for
chitosan and theophylline (Figure 7). The characteristic absorption peaks of the theophylline spectrum
at 1665–1550 cm−1 are derived from C–C and C–N bonds [18]. We found small and characteristic
absorption peaks for chitosan (as a pure material) and a peak with a higher intensity for the PM in the
same spectral region (Figure 7). This specific peak (1658 cm−1) is partially visible in the FTIR spectra of
the nanofibers produced by TES (F-I) and USES (F-II, III). The intensity of the characteristic peak of
theophylline at 1658 cm–1 for nanofibrous samples (F-II, F-III), however, is smaller than that observed
in the FTIR spectra of PM or pure theophylline powder.
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4. Conclusions
We compared traditional electrospinning (TES) and nozzleless ultrasound-enhanced electrospinning
(USES) as methods to fabricate nanofibrous polymeric drug delivery systems (DDSs). The physicochemical
and pharmaceutical properties of the nanofibrous DDSs were studied. Both methods can be applied
for aqueous-based fabrication of non-woven DDSs using PEO and chitosan as carrier polymers.
With USES, the evaporation of solvent is advanced by using a high-intensity focused US enabling
acoustic streaming and thermal effect inside the solution. Therefore, USES is associated with more
pronounced process-induced solid-state changes of the materials compared to those induced by TES.
Nanofibers generated by USES are amorphous, whereas the nanofibers produced by TES are less
prone to being amorphous. The controlled phase transformation of higher-energy amorphous form
is especially poorly applicable for water-soluble drugs. Further research is needed to discover all
potential strengths and limitations of USES in fabricating nanofibrous DDSs.
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